Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Ozanimod and fingolimod are sphingosine 1-phosphate receptor–modulating therapies for relapsing multiple sclerosis. Patients & methods: Comparative effectiveness was assessed by matching adjusted indirect comparisons of safety and efficacy trial outcomes at first-dose cardiac monitoring, 1 year and 2 years. Results: After adjustment, baseline characteristics were similar. Ozanimod was associated with a lower risk of extended first-dose monitoring, conduction abnormalities including atrioventricular block. One-year risks of any adverse event (AE), mean lymphocyte count reductions and abnormal liver enzymes were lower with ozanimod. Two-year risks of AEs leading to discontinuation, any AEs, herpetic infections, bradycardia and abnormal liver enzymes were lower with ozanimod. Analyses of efficacy outcomes were similar. Conclusion: Ozanimod appears to have a favorable benefit-risk profile versus fingolimod.
Supplementary Material
File (suppl_data.zip)
- Download
- 36.20 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Von Bismarck O, Dankowski T, Ambrosius B et al. Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurol. Neuroimmunol. Neuroinflamm. 5(3), e446 (2018).
2.
Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol. Neuroimmunol. Neuroinflamm. 3(5), e279 (2016).
3.
Lublin FD, Reingold SC, Cohen JA et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3), 278–286 (2014).
4.
Olek M, Howard J. Clinical presentation, course, and prognosis of multiple sclerosis in adults. https://www.uptodate.com/contents/clinical-presentation-course-and-prognosis-of-multiple-sclerosis-in-adults
5.
European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf
6.
Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61(11), 1528–1532 (2003).
7.
Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. Brain health: time matters in multiple sclerosis. Mult. Scler. Relat. Disord. 9(Suppl. 1), S5–S48 (2016).
8.
Ziemssen T, Derfuss T, De Stefano N et al. Optimizing treatment success in multiple sclerosis. J. Neurol. 263(6), 1053–1065 (2016).
9.
Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 48(1), 74–80 (1997).
10.
Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: a case-control study. J. Clin. Pharm. Ther. 26(6), 437–444 (2001).
11.
Gehr S, Kaiser T, Kreutz R, Ludwig W-D, Paul F. Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials. EPMA J. 10(4), 425–436 (2019).
12.
Finkelsztejn A. Multiple sclerosis: overview of disease-modifying agents. Perspect. Medicin. Chem. 6, 65–72 (2014).
13.
Straus Farber R, Harel A, Lublin F. Novel agents for relapsing forms of multiple sclerosis. Annu. Rev. Med. 67, 309–321 (2016).
14.
Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin. Med. (Lond.) 17(6), 530–536 (2017).
15.
Gilenya [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ (2019). https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gilenya.pdf
16.
Rasche L, Paul F. Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opin. Pharmacother. 19(18), 2073–2086 (2018).
17.
Cohen JA, Comi G, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. (2019) (Epub ahead of print).
•• In RADIANCE, a 2-year, Phase III clinical trial of ozanimod versus IFNβ-1a in patients with relapsing multiple sclerosis, ozanimod demonstrates greater efficacy on both MRI and clinical disease measures.
18.
Comi G, Kappos L, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. (2019) (Epub ahead of print).
•• In SUNBEAM, a Phase III clinical trial comparing ozanimod versus IFNβ-1a in patients with relapsing multiple sclerosis, ozanimod demonstrates superiority to IFNβ-1a on relapse and MRI end points.
19.
Signorovitch J, Erder MH, Xie J et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol. Drug Saf. 21(Suppl. 2), 130–137 (2012).
20.
Signorovitch JE, Wu EQ, Yu AP et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935–945 (2010).
• In the absence of head-to-head trials, matching-adjusted indirect comparisons can be performed. An example applied to psoriasis treatment is explained here.
21.
Fox RJ, Cutter G, Chan A et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis [abstract PND10]. Value Health 18(7), A750 (2015).
22.
Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr. Med. Res. Opin. 35(8), 1371–1378 (2019).
23.
Cohen JA, Comi G, Selmaj KW et al. Ozanimod vs interferon β-1a: clinical and MRI results of RADIANCE part B - a 2-year phase 3 trial in relapsing multiple sclerosis [abstract 280]. Mult. Scler. J. 23(Suppl. 3), 981–982 (2017).
24.
Cree B, Selmaj K, Kopicko J et al. The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics [abstract]. Neurology 88(Suppl. 16), P6.344 (2017).
25.
Comi G, Kappos L, Selmaj KW et al. Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM) [abstract 232]. Mult. Scler. J. 23(Suppl. 3), 73–74 (2017).
26.
Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402–415 (2010).
• A Phase II study in patients with multiple sclerosis that shows the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular IFNβ-1a.
27.
Kappos L, Radue EW, O'connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
• In a 2-year analysis of Phase II and III studies of patients with relapsing-remitting multiple sclerosis, oral fingolimod improved the relapse rate, the risk of disability progression and end points on MRI compared with placebo.
28.
Calabresi PA, Radue EW, Goodin D et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13(6), 545–556 (2014).
• A Phase III clinical trial in patients with relapsing-remitting multiple sclerosis, in which fingolimod was associated with reductions in clinical and MRI disease activity compared with placebo.
29.
Dimarco JP, O'connor P, Cohen JA et al. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult. Scler. Relat. Disord. 3(5), 629–638 (2014).
30.
Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69(2), 292–302 (2011).
31.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444–1452 (1983).
Information & Authors
Information
Published In
Pages: 275 - 285
PubMed: 31948278
Copyright
© 2020 Elyse Swallow. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 13 November 2019
Accepted: 19 December 2019
Published online: 17 January 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0169
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- David T Rubin, Silvio Danese, Hiroshi Nakase, Ryan C Ungaro, Douglas C Wolf, Olga Alekseeva, AnnKatrin Petersen, Zhaohui Liu, Dimpy Mehra, Anjali Jain, Mark T Osterman, Anthony Krakovich, Jon V Riolo, Erik DeBoer, James Appio, Preetika Sinh, Bruce A C Cree, Jeffrey A Cohen, Peter Irving, Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis, Inflammatory Bowel Diseases, 10.1093/ibd/izaf319, (2026).
- Jessica Cooperrider, Jeffrey Lambe, Michelle Chu, Mengke Du, Jennifer Reardon, Burhan Chaudry, Andrew Thorpe, Carrie M. Hersh, Devon Conway, Real-world experience of ozanimod in adults with multiple sclerosis, Neurodegenerative Disease Management, 10.1080/17582024.2026.2622078, (1-9), (2026).
- Qinhui Tang, Xiaowei Tang, Xinyue Hu, Wenmeng Yin, Lian Luo, Yantong Li, Xiaolin Zhong, A real-world data analysis of Ozanimod in the FDA Adverse Event Reporting System (FAERS) database, Medicine, 10.1097/MD.0000000000044535, 104, 37, (e44535), (2025).
- Giorgia Teresa Maniscalco, Maddalena Sparaco, Maria Di Gregorio, Giuseppina Cafasso, Elisabetta Signoriello, Felice Romano, Rosa Iodice, Roberta Fantozzi, Paolo Bellantonio, Aurora Zanghi, Leonardo Sinisi, Alessandro D’Ambrosio, Vincenzo Busillo, Valentina Scarano, Rocco Capuano, Luigi Lavorgna, Michela Williams, Antonio De Martino, Maria Elena Di Battista, Daniele Di Giulio Cesare, Giacomo Lus, Emanuele Cassano, Paola Sofia Di Filippo, Grazia Sibilia, Gianmarco Abbadessa, Vincenzo Andreone, Simona Bonavita, Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study, Journal of Neurology, 10.1007/s00415-025-13300-z, 272, 9, (2025).
- Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi, Aurora Zanghì, Emanuele D’Amico, Roberta Fantozzi, Diego Centonze, Giacomo Lus, Switch from fingolimod to ozanimod for safety or intolerance reasons, Therapeutic Advances in Neurological Disorders, 10.1177/17562864251328191, 18, (2025).
- Federica Galota, Simone Marcheselli, Sara De Biasi, Lara Gibellini, Francesca Vitetta, Alessia Fiore, Krzysztof Smolik, Giulia De Napoli, Martina Cardi, Andrea Cossarizza, Diana Ferraro, Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells, Cells, 10.3390/cells14080606, 14, 8, (606), (2025).
- Nunzia Balzano, Raffaella Di Napoli, Federica Fraenza, Daniele Di Giulio Cesare, Ornella Moreggia, Mirko Cardillo, Cristina Scavone, Giorgia Teresa Maniscalco, Annalisa Capuano, Liberata Sportiello, Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data, Pharmacological Reports, 10.1007/s43440-025-00725-6, 77, 3, (775-788), (2025).
- Ying Li, Jingmin Zhang, Guangrui Yang, Shujie Jiao, Mingyuan Guan, Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system, International Immunopharmacology, 10.1016/j.intimp.2025.114520, 153, (114520), (2025).
- Nicola Humphry, Ozanimod in Relapsing Multiple Sclerosis: New Insights, American Medical Journal Neurology, 10.33590/neurolamj/NITU6060, (2024).
- Tina Nie, Yahiya Y. Syed, Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis, CNS Drugs, 10.1007/s40263-024-01116-w, 38, 11, (931-941), (2024).
- See more